Bibliography
- Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(Suppl 5):S1-85
- Sorensen TI. The changing lifestyle in the world. Body weight and what else? Diabetes Care 2000;23 (Suppl 2):B1-4
- Leiter LA, Barr A, Belanger A, et al. Diabetes Screening in Canada (DIASCAN) Study. Diabetes Care 2001;24:1038-43
- Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70(1):90-7
- UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-13
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of both macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713-20
- The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
- Canadian Diabetic Association 2008 Clinical Practice Guidelines. Available from: http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf, Can J Diabet September 2008;32
- Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86(1):280-8
- Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000;17(1):40-7
- Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283(13):1695-702
- Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24(7):1226-32
- GlaxoSmithKline. Highlights of Prescribing Information. Research Triangle Park, NC, USA; 2008. Accessible from: http://us.gsk.com/products/assets/us_avandia.pdf [Accessed 1 August 2008]
- The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105
- Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43
- Shvidel L, Arcavi L, Sigler E. Symptomatic anemia induced by rosiglitazone. Eur J Intern Med 2007;18:348
- Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007;82(3):275-81
- Ferrannini E, Dormandy J. Results of PROactive. Program and abstracts of the European Association for the Study of Diabetes 41st Annual Meeting; September 12-15, 2005; Athens, Greece
- PROactive study results. Available from: www.Proactive-results.com [Accessed 23 September 2005]
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71